cyborg1298 schreef op 23 september 2014 20:00:
Ik begrijp alleen het persbericht niet zo goed:
Quote: "If the interim analysis demonstrates poor accrual, or fails to demonstrate a substantially decreased repeat biopsy rate, the LCD indicates that limited coverage will continue until either 1,200 patients have been tested or 3 years from the effective date of the LCD, which ever occurs first. MDxHealth expects to have tested 1,200 patients within the PASCUAL trial and the Registry by Q2 2016. Unrestricted Medicare coverage, with the Registry requirement removed, is expected with favorable PASCUAL trial findings."
Staat hier nu dat als MDX niet voldoende resultaat boekt binnen het PASCUAL programma, de coverage binnen maximaal 3 jaar komt te vervallen of na 1200 patienten.
Hoor graag jullie mening...